What is the 13F Pro Quality Score for IOVA?

13F Pro ranks IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IOVA's current score at https://13fpro.ai/research/IOVA (free sign-up required for the full ranking).

Which hedge funds own the most IOVA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IOVA include BlackRock,, MHR FUND MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IOVA as soon as new 13F filings post.

Where does 13F Pro source IOVA data?

All IOVANCE BIOTHERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. IOVANCE BIOTHERAPEUTICS, INC. files with the SEC under CIK 1425205. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IOVA in?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IOVA research updated on 13F Pro?

IOVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IOVANCE BIOTHERAPEUTICS, INC.(IOVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1425205 IOVA stock profile & AI dashboard →

13F Pro Quality Score

30.6/100

Rank #2,344 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

95.1/100

Profitability

6.1/100

Balance Sheet

4.2/100

Earnings Quality

30.0/100

Free Cash Flow

5.9/100

Institutional Flow

58.4/100

Revenue Scale

26.9/100

Dilution Risk

8.1/100

IOVA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IOVANCE BIOTHERAPEUTICS, INC. (IOVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IOVA at 30.6/100 on a 32-signal composite quality model, placing it at rank #2,344 of 2,879 stocks — the bottom half of the AI-ranked universe. IOVA scores in the top quartile across revenue growth (95.1). Areas of concern include balance sheet strength (4.2) and free cash flow (5.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), IOVANCE BIOTHERAPEUTICS, INC. reports quarterly revenue of $71.4M, net income of $-79.0M, free cash flow of $-78.7M. Top institutional holders of IOVA by reported 13-F value include BlackRock,, MHR FUND MANAGEMENT, STATE STREET, based on the most recent SEC filings. IOVA trades on the Nasdaq exchange and files with the SEC under CIK 1425205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IOVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IOVANCE BIOTHERAPEUTICS, INC. directly from SEC EDGAR. IOVANCE BIOTHERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 8 and 93 since 2024, currently 30.6 — a declining long-term trajectory across 44 quarterly and live scoring snapshots.

✦

Fun facts about IOVANCE BIOTHERAPEUTICS, INC.

Quirks, history, and lore behind IOVA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · focused on cell therapy for cancer patients.
2
The Numbers
Its first commercial product only recently launched, meaning revenue is still ramping from near zero — yet the company carries a market cap in the low billions on the promise of its pipeline.
3
The History
Founded in the 2010s, the company spent years in clinical trials before winning FDA approval for a treatment targeting a notoriously hard-to-treat skin cancer.
4
The Secret
Its core technology uses a patient's own tumor-infiltrating lymphocytes — immune cells extracted, multiplied in a lab, and infused back — essentially turning the body into its own cancer-fighting factory.
5
The Lore
Its first approved therapy, Amtagvi, made history in early 2024 as the first TIL cell therapy ever greenlit by the FDA — a milestone the oncology world had been watching for decades.
6
The Giveaway
Ticker IOVA, pioneer of TIL therapy, and the company whose name literally starts with the Latin root for "violet" — as in melanoma, the dark-pigmented cancer it set out to conquer.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$71.4M

Net Income

Q1 2026

$-79.0M

Free Cash Flow

Q1 2026

$-78.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+22061.6% YoY

$263.5MFY 2025

FY21 —FY22 —FY23 $1.2MFY25 $263.5M

Net Income

+11.9% YoY

$-391.0MFY 2025

FY21 $-342.3MFY22 $-395.9MFY23 $-444.0MFY25 $-391.0M

Operating Income

+12.4% YoY

$-403.4MFY 2025

FY21 $-342.7MFY22 $-398.9MFY23 $-460.6MFY25 $-403.4M

EPS (Diluted)

+42.3% YoY

$-1.09FY 2025

FY21 $-2.23FY22 $-2.49FY23 $-1.89FY25 $-1.09

Total Assets

+17.0% YoY

$913.2MFY 2025

FY21 $777.3MFY22 $664.0MFY23 $780.4MFY25 $913.2M

Op. Cash Flow

+16.4% YoY

$-302.4MFY 2025

FY21 $-227.9MFY22 $-292.8MFY23 $-361.8MFY25 $-302.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$263.5M +22061.6%	$1.2M	—	—	—	$0.00
Net Income	$-391.0M +11.9%	$-444.0M -12.2%	$-395.9M -15.7%	$-342.3M -31.8%	$-259.6M -110.1%	$-123.6M
Operating Income	$-403.4M +12.4%	$-460.6M -15.5%	$-398.9M -16.4%	$-342.7M -30.8%	$-261.9M -104.2%	$-128.3M
EPS (Diluted)	$-1.09 +42.3%	$-1.89 +24.1%	$-2.49 -11.7%	$-2.23 -18.6%	$-1.88	—
Total Assets	$913.2M +17.0%	$780.4M +17.5%	$664.0M -14.6%	$777.3M +1.2%	$768.5M +59.8%	$480.8M
Operating Cash Flow	$-302.4M +16.4%	$-361.8M -23.6%	$-292.8M -28.4%	$-227.9M -11.1%	$-205.1M -102.6%	$-101.2M

AI Insight: IOVA Financial Trends

IOVA's Q4 2025 operating loss narrowed to its best level yet at -$73M, but Q1 2026 revenue of $71M marks a familiar sequential step-down that keeps profitability distant.

• Operating loss improved materially from -$102M in Q2 2024 to -$73M in Q4 2025, suggesting meaningful operating leverage as revenue scaled.

• Revenue grew from $31M in Q2 2024 to $87M in Q4 2025, but each Q1 resets sharply lower — $49M in Q1 2025 and $71M in Q1 2026.

• Operating cash burn improved from -$98M in Q2 2024 to -$53M in Q4 2025, though Q1 2026 burn widened again to -$72M.

• Equity has drifted from $769M in Q2 2024 to $722M in Q1 2026, reflecting cumulative net losses steadily eroding the capital base.

⚠ Recurring Q1 revenue drop — $49M in Q1 2025, $71M in Q1 2026 — suggests seasonal or operational constraints that could delay breakeven.

⚠ No debt reported across all periods; watch for any new financing as equity erosion continues and cash burn persists.

⚠ Q4 2025 showed the tightest operating loss at -$73M with $87M revenue — confirm whether Q1 2026 step-back is structural or one-time.

AI Insight: IOVA Ratio Trends

Q4 2025 marked the best quarterly operating margin at -84.7%, but Q1 2026 deteriorated to -113.5%, signaling no sustained profitability trajectory yet.

• Operating margin improved sharply from -189.8% in Q2 2025 to -84.7% in Q4 2025, before widening again to -113.5% in Q1 2026.

• ROE improved from -63.9% in Q2 2025 to -41.2% in Q4 2025, then slightly deteriorated to -43.8% in Q1 2026.

• ROIC remains deeply negative across all periods, ranging from -42.1% in Q4 2025 to -65.1% in Q2 2025, with no D/E data available.

⚠ Q1 2026 operating margin rewidened to -113.5% after Q4 2025's relative improvement — early signs of seasonal or structural headwinds.

⚠ No D/E data available across any period, limiting visibility into leverage and balance sheet risk.

Get alerted when IOVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IOVANCE BIOTHERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IOVA

BlackRock, Inc.
$109.1M31,080,505 sh
MHR FUND MANAGEMENT LLC
$101.7M28,967,103 sh
STATE STREET CORP
$61.2M17,448,108 sh
VANGUARD CAPITAL MANAGEMENT LLC
$58.3M16,617,737 sh
TWO SIGMA INVESTMENTS, LP
$48.0M13,687,433 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$41.1M11,700,844 sh
MILLENNIUM MANAGEMENT LLC
$33.0M9,414,292 sh
GOLDMAN SACHS GROUP INC
$30.7M8,760,060 sh
GEODE CAPITAL MANAGEMENT, LLC
$30.1M8,572,598 sh
Invenomic Capital Management LP
$29.8M8,495,551 sh

Fund	Value	Shares
BlackRock, Inc.	$109.1M	31,080,505
MHR FUND MANAGEMENT LLC	$101.7M	28,967,103
STATE STREET CORP	$61.2M	17,448,108
VANGUARD CAPITAL MANAGEMENT LLC	$58.3M	16,617,737
TWO SIGMA INVESTMENTS, LP	$48.0M	13,687,433
VANGUARD PORTFOLIO MANAGEMENT LLC	$41.1M	11,700,844
MILLENNIUM MANAGEMENT LLC	$33.0M	9,414,292
GOLDMAN SACHS GROUP INC	$30.7M	8,760,060
GEODE CAPITAL MANAGEMENT, LLC	$30.1M	8,572,598
Invenomic Capital Management LP	$29.8M	8,495,551

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IOVA on your watchlist

Track score changes the day IOVANCE BIOTHERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IOVA a good stock to buy?

13F Pro's AI-powered analysis of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IOVA are available on the IOVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IOVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IOVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IOVANCE BIOTHERAPEUTICS, INC.'s investment landscape.